The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven, Director General of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access in European markets.
In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy that may come from this tumultuous period.
Drug shortages can greatly impact patients and the pharmaceutical industry. Adrian van den Hoven, Director General of Medicines for Europe, explains how to prevent and reduce the effects of medicinal scarcities in the EU.
Arun Narayan is the Chairman of the Value Added Medicines Sector Group at Medicines for Europe, in addition to serving as Head of Global Portfolio Strategy and Head of European Business Operations at Mylan. Narayan introduces compelling reasons why payers in Europe should consider Value Added Medicines, including cost savings and improved rates of adherence, and underscores the importance of leveraging real-world evidence to demonstrate their value.
Since the first treatment was approved in 2006, Europe has been at the vanguard of the biosimilar medicines sector, approving more treatments over the last 10 years than anywhere else in the world. However, it is only in the last few years that usage has significantly increased, and biosimilars have begun to challenge the established order of care, bringing meaningful access to medicines for patients.
Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas and have provided massive savings for healthcare systems in Europe. In this exclusive interview with Adrian van den Hoven, director general of Medicines for Europe, we discuss the importance of the generic industry, the disparity in generic penetration among the member states and how the Value-Added Medicine Group will improve the lives of patients struggling to manage their disease.
An SPC manufacturing waiver should be extremely beneficial for Europe and will increase net sales of the EU pharmaceutical industry…